title: 'Multidrug'-resistant tuberculosis. It is time to focus on the private sector of medicine.
authors.forename: J A
authors.initials: JA
authors.lastname: Sbarbaro
mesh_terms: D000995:Antitubercular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002985:Clinical Protocols; D004338:Drug Combinations; D004352:Drug Resistance, Microbial; D006801:Humans; D007388:Internal Medicine; D007391:International Cooperation; D007538:Isoniazid / Q000008:administration & dosage / Q000627:therapeutic use; D010349:Patient Compliance; D011331:Private Practice; D019233:Retreatment; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D012955:Societies, Medical; D009626:Terminology as Topic; D018088:Tuberculosis, Multidrug-Resistant / Q000145:classification / Q000517:prevention & control*; D014397:Tuberculosis, Pulmonary / Q000517:prevention & control*
chemical_list: D000995:Antitubercular Agents; D004338:Drug Combinations; D007538:Isoniazid; D012293:Rifampin